PPT-SOF/VEL/VOX

400100100 mg QD N 263 N 152 W12 Placebo gt 18 years Chronic HCV infection Genotype 1 2 3 4 5 or 6 NS5A inhibitorexperienced for 4 weeks exclusion if discontinued due to an adverse. Director, J6/CIO . United States Special Operations Command. SOF C4. “One Force, . One Environment”. UNCLASSIFIED. UNCLASSIFIED. 8,463. DEPLOYED. 80. LOCATIONS. 24/7. 64,000. . SOF. Unified Commands. Versatile . Efficient. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). 4 Partners: . This program is s. upported. by educational grants from AbbVie; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and . ViiV. Healthcare. . About These Slides. Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients. for 12 weeks in liver transplant recipients with genotype 1-4. Agarwal K. J . Hepatol. . 2018;69:603-7. SOF/VEL: 400/100 mg 1 . tablet. QD. Liver transplant recipients. Recurrent HCV infection after transplantation. Visit us at vox.co.za CONCLUSIONThis will result in a ‘new’ normal inuenced by the learnings gained from this period of remote working. Companies will likely have to introduce a more &# NEVO+1200 M DATA SHEET _______________________________________________________________________________________________ DOC - DTS - 004 - 03, NEVO+1200M Medical Datasheet Vox Power Limited | Unit 2, Re >. 18 years. Genotype 2, 3, 4, 5 or 6. HCV RNA . >. 10 000 IU/mL. Treatment-naive or treatment-experienced (with or without DAA). Compensated cirrhosis allowed. Creatinine clearance . >. 60 mL/min.